PolyPid Analyst Ratings
H.C. Wainwright Maintains PolyPid(PYPD.US) With Buy Rating, Maintains Target Price $14
Buy Rating Affirmed for PolyPid on D-PLEX's Positive Trial Milestones and Commercial Prospects
JMP Securities Maintains PolyPid(PYPD.US) With Buy Rating, Maintains Target Price $13
Barclays Maintains PolyPid(PYPD.US) With Hold Rating, Maintains Target Price $10
PolyPid (PYPD) Receives a Hold From Barclays
PolyPid Analyst Ratings
Buy Rating Affirmed for PolyPid on D-PLEX Clinical Progress and Potential Early Approval
H.C. Wainwright Maintains PolyPid(PYPD.US) With Buy Rating, Maintains Target Price $14
JMP Securities Maintains PolyPid(PYPD.US) With Buy Rating, Maintains Target Price $13
Buy Rating Affirmed for PolyPid Amidst Strong Trial Progress and Robust Financial Position
PolyPid Analyst Ratings
Analysts Conflicted on These Healthcare Names: Abbott Laboratories (ABT), PolyPid (PYPD) and GoodRx Holdings (GDRX)
PolyPid Analyst Ratings
Analysts Offer Insights on Healthcare Companies: PolyPid (PYPD) and Cartesian Therapeutics (RNAC)
Analysts Offer Insights on Healthcare Companies: PolyPid (PYPD) and Clene (CLNN)
PolyPid Analyst Ratings
Buy Rating Affirmed for PolyPid on Strong Trial Progress and Expanding Pipeline Potential
Analysts Have Conflicting Sentiments on These Healthcare Companies: HCA Healthcare (HCA), PolyPid (PYPD) and Eli Lilly & Co (LLY)
Analysts Offer Insights on Healthcare Companies: Anavex Life Sciences (AVXL), PolyPid (PYPD) and Nyxoah (NYXH)
No Data
No Data